WeVote
Log In

Bill

Bill

S 371

SBA Disaster Transparency Act

119th Congress Introduced by Marsha Blackburn and 6 co-sponsors

Bill S 371 allows wholesale importation of prescription drugs from licensed foreign suppliers, aiming to lower costs for consumers while ensuring safety and compliance.

Committee on Small Business and Entrepreneurship. Reported by Senator Ernst without amendment. Without written report.
0
WeVote Research Nonpartisan
Bill Summary · S 371

Summary of Bill S 371: Wholesale Prescription Drug Importation Program

Purpose and Intent

Bill S 371 aims to establish a wholesale prescription drug importation program. The primary goal of this legislation is to reduce the cost of prescription medications for consumers by allowing the importation of drugs from licensed suppliers in other countries. This initiative seeks to enhance access to affordable medications while ensuring safety and compliance with regulatory standards.

Key Provisions

  • Wholesale Importation: The bill authorizes the importation of prescription drugs in bulk from approved foreign suppliers.
  • Regulatory Oversight: The program will be overseen by relevant health authorities to ensure that imported drugs meet safety and efficacy standards.
  • Cost Reduction: The legislation is designed to lower the overall cost of prescription drugs for consumers, potentially leading to significant savings.
  • Consumer Protection: Provisions are included to protect consumers from counterfeit or unsafe medications, ensuring that all imported drugs are properly vetted.

Affected Parties

  • Consumers: Individuals who rely on prescription medications will benefit from potentially lower prices.
  • Pharmaceutical Suppliers: Domestic suppliers may face increased competition from imported drugs, which could impact pricing strategies.
  • Health Authorities: Regulatory bodies will be tasked with overseeing the importation process and ensuring compliance with safety standards.

Legislative Timeline

  • Introduced: January 08, 2025
  • Referred to Health Committee: January 08, 2025
  • Reported and Committed to Finance: January 21, 2025
  • Advanced to Third Reading: March 13, 2025
  • Passed Senate: May 20, 2025
  • Delivered to Assembly: May 20, 2025
  • Referred to Higher Education: May 20, 2025

Related Legislation

  • A 7588: A prior-session bill addressing similar issues.
  • A 133: Another prior-session bill related to prescription drug pricing.
  • S 9838: A prior-session bill that may have overlapping objectives.
  • A 4604: A companion bill that may provide additional context or support for S 371.

Conclusion

Bill S 371 represents a significant step towards addressing the high costs of prescription medications through the establishment of a wholesale importation program. By allowing the importation of drugs from licensed foreign suppliers, the bill aims to enhance affordability and accessibility for consumers while maintaining strict safety regulations. The ongoing legislative process will determine the final structure and implementation of this program.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.